Country: Greece
Language: English
Source: HMA (Heads of Medicines Agencies)
domperidone 5 mg/ml
Laboratorios Dr. Esteve S.A.
QA03FA03
Oral suspension
domperidone
Dogs
2011-09-28
1/17 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2/17 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Leisguard 5 mg/ml Oral Suspension for Dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: ACTIVE SUBSTANCE: Domperidone 5 mg EXCIPIENTS: Methyl parahydroxybenzoate (E218) 1.80 mg Propyl parahydroxybenzoate (E216) 0.20 mg Quinoline yellow (E104) 0.20 mg For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Oral suspension Yellow suspension 4. CLINICAL PARTICULARS 4.1. TARGET SPECIES Dogs 4.2. INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES To reduce the risk of developing an active infection and clinical disease in case of contact with _Leishmania infantum_, through the enhancement of the cell-mediated immune response. The efficacy of the product has been demonstrated in dogs under multiple natural parasite exposure in zones with high infection pressure. Control of clinical progression of canine leishmaniosis at early stages of the disease (dogs with low to moderate positive antibody levels and mild clinical signs such as peripheral lymphadenopathy or papular dermatitis). 4.3. CONTRAINDICATIONS 3/17 Do not use whenever stimulation of gastric motility might be dangerous eg. In the presence of gastrointestinal haemorrhage, mechanical obstruction or perforation. Do not use in animals with a known hypersensitivity to domperidone or any of the excipients. Do not use in animals with prolactin-secreting pituitary tumor. Domperidone Read the complete document
1/17 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2/17 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Leisguard 5 mg/ml Oral Suspension for Dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: ACTIVE SUBSTANCE: Domperidone 5 mg EXCIPIENTS: Methyl parahydroxybenzoate (E218) 1.80 mg Propyl parahydroxybenzoate (E216) 0.20 mg Quinoline yellow (E104) 0.20 mg For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Oral suspension Yellow suspension 4. CLINICAL PARTICULARS 4.1. TARGET SPECIES Dogs 4.2. INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES To reduce the risk of developing an active infection and clinical disease in case of contact with _Leishmania infantum_, through the enhancement of the cell-mediated immune response. The efficacy of the product has been demonstrated in dogs under multiple natural parasite exposure in zones with high infection pressure. Control of clinical progression of canine leishmaniosis at early stages of the disease (dogs with low to moderate positive antibody levels and mild clinical signs such as peripheral lymphadenopathy or papular dermatitis). 4.3. CONTRAINDICATIONS 3/17 Do not use whenever stimulation of gastric motility might be dangerous eg. In the presence of gastrointestinal haemorrhage, mechanical obstruction or perforation. Do not use in animals with a known hypersensitivity to domperidone or any of the excipients. Do not use in animals with prolactin-secreting pituitary tumor. Domperidone Read the complete document